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Abstract 
 
Aim 
To assess whether pre-operative botulinum toxin A (BTX-A) affects pain following major 
hip surgery for children with cerebral palsy (CP). 
 
Method 
Randomised, parallel arms, placebo-contolled trial. Children with hypertonic CP aged 2-
15 years awaiting bony hip surgery at a tertiary hospital were randomised to receive either 
BTX-A or placebo injections into the muscles of the hip on a single occasion immediately 
prior to surgery. The primary outcome was the Paediatric Pain Profile (PPP), which was 
assessed at baseline and weekly for six weeks. Treatment allocation was by minimisation. 
Participants, clinicians and outcome assessors were masked to group assignment.  
 
Results 
Twenty-seven participants (17 males; mean 8 years 8 months) were allocated to BTX-A 
and 27 (14 male; mean 8 years 11 months) to placebo. Mean (SD) PPP at six weeks for 
the BTX-A group (n=24 followed up) was 10.96 (7.22) and for the placebo group (n=26) 
was 10.04 (8.54) (p=0.69; 95% CI -4.82, 3.18). There were 16 serious adverse events in 
total during six months of follow-up (n=6 in BTX-A group).  
 
Interpretation 
Use of BTX-A immediately before bony hip surgery for reducing post-operative pain for 
children with CP was not supported.  
 
Trial registration 
EudraACT 2010-023240-33. 
 
Funding 
NIHR RfPB grant PB-PG-1208-18132. 
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What this paper adds 
 BTX-A does not reduce post-operative pain if used in this way. 
 BTX-A also does not affect post-operative quality of life. 
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Cerebral palsy (CP) is the commonest cause of physical disability in childhood. It affects 
up to three children per 1000 throughout Europe.1 The Gross Motor Function 
Classification System (GMFCS) describes their level of motor ability, and over 25% of 
children with CP are in the most severely affected groups, levels IV and V. These children 
are not independently ambulant and are more likely to have cognitive and communication 
difficulties and are at high risk of developing hip displacement, which causes pain for 
many children.2,3 Those children who present to orthopaedic services with progressive 
femoral head displacement require bony surgery (osteotomy) as long-term follow-up 
studies have demonstrated that this maintains the position of the femoral head in the 
acetabulum over time better than muscle surgery alone, and reduces the likelihood of a 
painful hip due to dislocation.4-7 
 
The management of pain in the severely neurologically impaired child undergoing hip 
surgery is challenging, and various strategies have been employed, including the use of 
post-operative epidurals.8,9 In a child with spasticity abnormally high post-operative 
muscle tone may cause painful muscle spasms.10 These involuntary and sustained muscle 
contractions are thought to contribute significantly to pain in children with CP. There are 
a number of treatments available for muscle spasm in cerebral palsy; all are systemic 
except botulinum toxin, which targets individual muscles by means of intramuscular 
injection. Botulinum toxin type A (BTX-A) injection is a well established and clinically 
effective treatment for muscle spasticity and the management of chronic pain in CP.11,12 
 
Research suggests it may have a beneficial effect in reducing post-operative pain due to 
spasticity.13-15 Barwood et al reported that BTX-A was effective in the post-operative 
period for children with cerebral palsy undergoing muscle surgeryonly.13. However, 
describing pain in children with cognitive impairment is challenging.16-19 Hunt et al. 
provided a validated pain profile questionnaire, the Paediatric Pain Profile (PPP), which 
measures pain in the more severely neurologically affected group of children with 
communication difficulties.19 Hunt demonstrated that an observer’s assessment of a 
child’s pain into different levels of severity (none, mild, moderate, severe or very severe) 
translated approximately into differences in scores on the PPP of ten points. The PPP 
provides for this group of children a user-friendly pain score, which was already in 
clinical use in our hospital. 
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The aim of this study was to test the hypothesis that BTX-A injections given to children 
with CP immediately prior to bony hip surgery affect pain experienced over a 6-week 
post-operative period. 
 
Methods 
Study Design 
This was a single centre, single surgeon, prospective, double-blind, parallel, superiority 
randomised placebo-controlled trial (RCT) with an even randomisation ratio, carried out 
in a United Kingdom tertiary children’s hospital. Ethical approval was awarded by the 
NES Research Ethics Committee for Wales (11/WA/0010). The trial was overseen by a 
Data Monitoring Committee.  
 
Participants 
The participants were recruited from children on the waiting list for hip surgery. Inclusion 
criteria included a diagnosis of bilateral hypertonic CP with GMFCS levels IV or V, aged 
2-15 years inclusive, who required bony hip surgery for displacement, and whose 
communication ability was appropriate for the use of the PPP. Patients were excluded if 
they had received intramuscular BTX-A within 4 months prior to surgery, had an acute 
and current systemic infection or illness, had a previous reaction to BTX-A, were likely to 
receive at the time of drug administration medications that might interact with BTX-A, or 
if their carers had insufficient understanding of English to complete the questionnaires. 
After screening, written information about the study including publication of results was 
given to the carers, and written consent for the trial was obtained at the pre-admission out-
patient appointment held a few weeks prior to surgery. 
 
Randomisation and masking (blinding) 
Participants were randomly allocated on the day of surgery to receive either BTX-A or 
placebo (saline injections) in an even ratio. Treatment allocation was carried out, 
independently of the research team, using a computerised minimisation procedure by 
King’s Clinical Trials Unit at King’s College London. This was stratified by age (above 
or below 7 years) and extent of surgery (unilateral or bilateral). An unmasked email was 
then automatically generated and sent to the clinical trials pharmacist and to the 
Medicines for Children Research Nurses (MCRN). Two of these nurses drew up the trial 
drug into six 1ml syringes: either BTX-A or placebo, both of which were clear colourless 
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liquids. All syringes were labelled ‘POPPIES trial drug’. The patient’s carers and families 
and all other staff were blinded, including the trial co-ordinator who collected the data. 
 
Procedures 
The trial drug injections were given by the surgeon under ultrasound guidance into the 
adductor longus and magnus muscles, medial hamstrings and iliopsoas muscles on both 
sides, after the patient was anaesthetised on the day of surgery. A dose of 12 units of 
Botox® (Allergan Ltd., Marlow, Buckinghamshire) per kilogram body weight was chosen 
in accordance with European Consensus statement 2009 for BTX-A in children with CP.20 
The dilution was 50 units per millilitre of saline. All patients received a total of 6 
injections (one site per muscle group). This meant that 2 units per kilogram could be used 
at each site, up to a total of 50 units at each site, and a total maximum of 300 units per 
child. There were no further BTX-A or placebo injections during the trial.  
 
Surgery for hip displacement was performed by one surgeon with assistants in accordance 
with established practice and surgical techniques.4,5 The indication for surgery was a 
migration index of more than 40%. Even if normal, the contralateral hip was also treated 
for patients under the age of 10 years and for those with contralateral windsweep. All 
patients had a femoral osteotomy and release of adductor longus and iliopsoas tendons. If 
required, an open reduction was performed through an anterior approach. An 
acetabuloplasty was performed if there was residual on-table instability. No cast was 
applied. Post-operatively, epidural analgesia was continued until the morning of the 
second post-operative day. If the epidural was not successful, a morphine infusion was 
used. Discharge was planned for the fourth post-operative day.  
 
PPP was recorded at the pre-operative clinical appointment, within 24 hours of surgery, 
before discharge from hospital, at weekly intervals (for 5 weeks) by telephone, and in the 
clinic at 6 weeks after surgery. A parent/carer analogue scale of pain was collected at the 
same time as the PPP. Health-related qualify of life, recorded using the Caregiver 
Priorities and Child Health Index of Life with Disabilities (CPCHILD), was measured at 
the outpatient clinic appointments pre-operatively and at 6 weeks after surgery. A log of 
analgesic medication was collected daily while an inpatient and at weekly intervals (for 5 
weeks) by telephone, and in the clinic at 6 weeks after surgery. Other outcomes were 
recorded weekly by telephone for 5 weeks and then in the clinic at 6 weeks.  
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Clinical examination of ranges of movement, radiographic measurement of hip 
displacement using the Reimers’ Migration Index (RMI)21,22 and dysplasia using the 
Acetabular Index (AI)23 were recorded at the baseline assessments, and at post-operative 
outpatient clinic appointments at 6 weeks, 3 months and 6 months after surgery as part of 
the routine management of these children. PPP and CPCHILD scores were also recorded 
at 3 and 6 months post-operatively. 
 
Outcomes 
The primary outcome measure was the PPP.19 This questionnaire scores pain by rating 
twenty items of observed behaviour on an ordinal scale of 0 (‘not at all’) to 3 (‘a great 
deal’) with a composite score of 0 to 60. Six weeks after surgery was chosen as the 
primary end point on the basis of previous literature, which suggested a peak effect of 
botulinum toxin approximately 3 weeks post injection, and our clinical experience of 
post-operative pain in this population.11,12 PPP was recorded at weekly time points to 
create a longitudinal measure of pain for each child and explore the optimal effects of 
BTX-A throughout this post-operative phase. 
 
The secondary outcomes included health-related quality of life using the CPCHILD 
questionnaire.24 This assesses health status, comfort, wellbeing and ease of caregiving of 
children with severe developmental disabilities, such as CP. The CPCHILD consists of 37 
items categorised into six sections: activities of daily living, positioning, transferring and 
mobility, comfort and emotions, communication and social interaction, health and overall 
quality of life. The caregiver rates each section based on the past two weeks. The 
maximum score is 100, and the higher the score the better the quality of life of the child. 
Other secondary outcomes included a parent/carer analogue scale of the child’s pain in the 
previous 24 hours (0 being no pain to 10 being worst pain imaginable), length of stay in 
hospital, use of analgesic medication, time until return to school or day-care, the child’s 
toleration of sitting in their usual chair and the number times the parents had to attend to 
their child during the night.  
 
Adverse events and serious adverse events were assessed by the CI with guidance from 
the King’s Health Partners Clinical Trials Office, recorded and reported to the Data 
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Monitoring Committee (DMC) and MHRA (Medicines and Healthcare Products 
Regulatory Agency, United Kingdom). 
 
Statistical analysis 
It was considered that a reduction in the PPP score of 10 points would be clinically 
significant. This was the minimum clinically significant difference and assumed a more 
conservative effect than found previously.11 This was also based on research that 
demonstrated that an observer’s assessment of a child’s pain into different levels of 
severity (none, mild, moderate, severe or very severe) translated approximately into 
differences in PPP scores of ten points.19 Power calculations were based on independent t-
tests between two normally distributed groups. The computer program 'G*Power 3' was 
used to perform the calculations. It was assumed that the mean pain score in the control 
was 40 points on the PPP and that the mean score in the treatment group was 30 points. 
The standard deviation in both groups was assumed to be 12 points, equating to a 
standardised difference of 0.83. With these parameters, a standard significance level of 
5% and power of 80%, the study required 24 patients in each group. The aim was to 
recruit 56 patients, 28 for each trial arm, allowing for a potential 15% loss to follow-up. 
The outcome was reported at multiple time points but the sample size calculation did not 
account for correlations between these measures. 
 
All analyses followed the intention-to-treat principle (analysis groups defined by 
participants’ random treatment allocation) and used Stata version 13. A significance level 
of 5% was used and all tests were two-sided. The primary outcome (PPP) and two 
secondary outcomes (CPCHILD and the parent/carer analogue pain scale) were analysed 
using linear mixed models. The dependent variable was outcome at the various post-
randomisation time points. The models’ independent variables were the two 
randomisation stratifiers (age category and extent of surgery), an indicator for time since 
randomisation, treatment group and an interaction between time and treatment group. In 
addition the models included a random intercept for participant. The analysis models used 
maximum likelihood and assumed that the missingness mechanism was missing at 
random. For the primary endpoint (six weeks after randomisation), the estimated 
treatment was calculated using a linear combination of coefficients. A single summary 
score of analgesic use for each participant was calculated by summing together a daily 
frequency score for simple (range of 0-4/day) and opioid analgesics (range of 0-3/day). 
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The opioids were given a weight of twice that of the simple analgesics. Five rounds of 
multiple imputation using chained equations (Stata command ‘ice’) were used to address 
missing analgesic data that were collected by telephone.25 The effect of treatment on the 
summed scores was investigated using multiple regression where the independent 
variables were trial arm and the minimisation stratifiers. Four outcomes that were not 
normally distributed (length of hospital stay, time to return to school or day-care, ability 
to tolerate sitting, and sleep disturbances) were analysed using the Mann-Whitney test. 
The statistician remained blind until the end of the analyses.  
 
Results 
Fifty-four participants were recruited from 21st September 2011 to 4th July 2014 (Figure 
1). Fifty-four participants were randomised to either botulinum toxin (n=27) or placebo 
(n=27). All of these were given the intervention and all but four (n=3 in botulinum toxin 
group) were followed up at the primary end point (6 weeks after randomisation). 
Summary statistics of the sample’s demographic and clinical characteristics are presented 
in Table 1. There was a substantial difference in GMFCS levels between the two 
treatment groups. Other demographic and clinical variables were well balanced, with the 
average number of co-morbidities of 3.98 for the treatment group and 4.59 for the placebo 
group. Incontinence (25 treatment group, 21 placebo group) followed by epilepsy (17 
treatment group, 16 placebo group) were the two most frequently reported co-morbidities 
for both groups.  
 
Table 1. Summaries of participants’ demographic and clinical data at baseline 
Variable Botulinum toxin 
(n=27) 
Placebo (n=27) 
Age (median; IQR) 8.3 (5.0-12.0) 8.1 (5.9-12.1) 
Age categories 
(n; %) 
≤7 years old 13 (48) 13 (48) 
>7 years olds 14 (52) 14 (52) 
Sex (n; %) Male 17 (63) 14 (52) 
Female 10 (37) 13 (48) 
Ethnicity (n; %) White 17 (63) 18 (67) 
Asian 0 (0) 3 (11) 
Black 7 (26) 4 (15) 
Other 3 (11) 2 (7) 
Extent of surgery 
(n; %) 
Unilateral 6 (22) 7 (26) 
Bilateral 21 (78) 20 (74) 
GMFCS (n; %) Level IV 4 (15) 14 (52) 
Level V 23 (85) 13 (48) 
PPP (mean; SD) 12.81 (7.43) 12.52 (7.05) 
CPCHILD (mean; SD) 50.74 (11.31) 53.39 (12.26) 
Right migration % (median; IQR) 
(n=46) 61 (30-86) 35 (23-68) 
Left migration % (SD) (n=47) 46 (24-73) 44 (30.5-83.5) 
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Right acetabular index (SD) (n=45) 33 (26-40) 26.5 (19-33.5) 
Left acetabular index (SD) (n=45) 32 (28-34) 32 (26.5-33) 
Parent analogue scale (mean; SD) 2.84 (2.64) 2.46 (2.32) 
Ability to tolerate sitting (minutes; 
median, IQR) 
180 (120-300) 210 (90-300) 
 Sleep disturbances per night 
(median, IQR) 
1 (0-3) 1 (0-3) 
 
 
Summaries of PPP, CPCHILD and the parent/carer analogue scale are provided in Table 
2; model-based estimated mean differences, p-values and 95% confidence intervals can be 
found in Table 3. The group differences in PPP were small at all time points (Table 2) and 
none, including at the primary end point, was found to be statistically significant (Table 
3). The estimated standardised group difference at six weeks after randomisation was 
0.11. The largest estimated difference was at two weeks after randomisation and was in 
favour of intervention, but there was no trend across all time points. 
 
 
Table 2. Summaries of outcomes by treatment arm and time point. 
Outcome 1 week 2 weeks 3 weeks 4 weeks 5 weeks 6 weeks 
Botulinum 
toxin 
Placebo Botulinum 
toxin 
Placebo Botulinum 
toxin 
Placebo Botulinum 
toxin 
Placebo Botulinum 
toxin 
Placebo Botulinum 
toxin 
Placebo 
PPP (mean; SD) 
 
14.61 
(8.55) 
14.42 
(8.34) 
10.32 
(6.47) 
13.46 
(9.36) 
10.77 
(8.24) 
9.92 
(7.26) 
7.65 
(5.23) 
7.71 
(6.29) 
9.71 
(7.23) 
9.50 
(8.66) 
10.96 
(7.22) 
10.04 
(8.54) 
CPCHILD (mean; SD)           57.60  
(12.95) 
55.24  
(12.93) 
Parent analogue scale 
(mean; SD) 
3.88  
(2.56) 
3.88  
(2.69) 
3.13  
(2.38) 
3.46  
(2.04) 
3.27  
(2.64) 
2.92  
(2.08) 
2.55  
(1.61) 
2.04  
(1.99) 
2.79  
(2.15) 
2.38  
(2.37) 
2.29  
(2.10) 
2.65  
(2.33) 
 
 
 
 
Table 3. Estimated treatment differences by time since randomisation. 
Outcome 1 week 2 weeks 3 weeks 4 weeks 5 weeks 6 weeks 
EMD (95% 
CI) 
p-value EMD (95% 
CI) 
p-value EMD (95% 
CI) 
p-value EMD (95% 
CI) 
p-value EMD (95% 
CI) 
p-value EMD (95% 
CI) 
p-value 
PPP 
 
0.46 (-3.57, 
4.50) 
0.82 -3.50 (-7.61, 
0.62) 
0.10 0.32 (-3.77, 
4.41) 
0.88 -0.07 (-4.25, 
4.12) 
0.98 0.09 (-3.96, 
4.15) 
0.97 0.82 (-3.18, 
4.82) 
0.69 
CPCHILD 
 
          3.34 (-2.77, 
9.45) 
0.28 
Parent analogue 
scale 
0.31 (-0.95, 
1.58) 
0.63 -0.66 (-1.96, 
0.64) 
0.32 0.33 (-0.96, 
1.62) 
0.62 0.59 (-0.76, 
1.93) 
0.39 0.53 (-0.76, 
1.81) 
0.42 -0.19 (-1.46, 
1.07) 
 
0.77 
EMD: Estimated mean difference (botulinum toxin minus placebo) 
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There was no statistically significant difference between the treatment groups for 
CPCHILD. The standardised group difference was 0.28. The parent/carer analogue scale 
also showed no significant group differences. The largest group difference was at two 
weeks after randomisation but this was not consistent with the overall trend of a lack of 
effect.  
 
There was slightly higher use of analgesics in the BTX-A arm (mean 68.7, SD 24.0) 
compared to placebo (mean 63.9; SD 17.7). The estimated difference was not significant 
(mean difference of 5.02; 95% CI -6.71, 16.75, p=0.39). There was no difference in length 
of hospital stay (median 5 days (IQR 4-7) in BTX-A arm and 5 days (IQR 5-6) in placebo 
arm; z=-0.11, p=0.91), in time until return to school/day-care (median 34 days (IQR 22-
49) in BTX-A arm and 38 days (IQR 28-43) in placebo arm; z=0.50), or ability to tolerate 
sitting at 6 weeks (median 240 minutes (IQR 210-420) in BTX-A arm and 300 minutes 
(IQR 180-420) in placebo arm; z=0.85, p=0.39). There was no evidence of a treatment 
difference in number of sleep disturbances per night at 6 weeks (median 1 occasion (IQR 
0-3) in BTX-A arm and 1 occasion (IQR 0-3) in placebo arm; z=-0.14; p=0.89).  
 
There were 16 serious adverse events in total during a 6-month follow-up period, with 
slightly fewer (n=6) in the BTX-A trial arm. There was one death in the placebo arm 
(n=1). Other events were prolonged hospital stay (n=5), hospitalisation (n=8), seizures 
(n=1) and pyrexia (n=1). There were 302 adverse events in total (n=156 in BTX-A toxin 
group). Of these, none were related to trial drug, and 219 were unremarkable 
postoperative findings. There was no evidence of a relationship between trial arm and 
intensity of AEs (χ2(2)=0.83, p=0.66). 
 
Discussion 
This was a randomised double-blind placebo-controlled trial to study the effect of 
preoperative BTX-A on post-operative pain in children with cerebral palsy. The trial 
demonstrated no difference when using a validated and widely used pain score (the PPP), 
and a robust methodology and statistical analysis. This result is supported by the 
secondary outcomes, i.e. the CPCHILD quality of life index and a simple pain score out 
of 10. Therefore the evidence does not support the technique described here as an 
effective strategy for managing this difficult recovery period for these complex patients. 
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In their randomised placebo-controlled study of 16 children, Barwood et al recorded a 
reduction in pain following adductor release surgery if 8 units per kilogram of Botox® 
BTX-A was injected bilaterally into the adductor muscle area beforehand.13 This was a 
small trial with no formal blinding, and the post-operative pain was measured by the 
nurses and trial coordinator using a score out of 3 and the post-operative analgesia that 
was given. Nevertheless we found it compelling enough to conduct a larger trial following 
more major surgery. In their study the muscles released at surgery had also been target by 
the trial drug, so we thought it clinically and methodologically sound to do the same. 
 
In the Barwood cohort the BTX-A was injected 5-10 days in advance of surgery, and the 
reduction in pain was recorded mainly during the first 48 hours, when painful spasms are 
normally at their worst. We considered injection of BTX-A in advance because of its 
delayed onset, but ethically we could not justify it. In any case, if there was an effect, it 
should have been detected by the pain scores during the weeks that followed discharge, as 
BTX-A is known to have an effect over a number of months. We recorded a maximum 
but not statistically significant difference in pain scores between the groups after 2 weeks, 
and this could fit with the expected effect of the BTX-A. 
 
The surgery conducted for the Barwood patients was considerably less extensive than for 
our patients, and they used double the dose of BTX-A spread over 2 sites per muscle 
group. We acknowledge therefore that we might have had a positive result if we had used 
a larger dose and used more than one injection site, as these are relatively large muscles. 
On the other hand our injections were arguably more accurate, as they were guided by 
ultrasound and performed under general anaesthetic. 
 
 
Although the PPP is well validated, it may be argued that it is not sensitive enough to 
detect a difference between the two groups. It was intended for the measurement of 
chronic pain, rather than pain in the acute post-operative period. BTX-A has been shown 
to be useful for pain management for the chronic pain of cerebral palsy.11 A difference in 
post-operative pain might be detectable using a pain score designed for this purpose. 
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Although we are anecdotally aware of the common use of BTX-A for post-operative pain 
management after major hip surgery, we have been unable to demonstrate its benefit. 
 
Protocol and trial registration 
The trial protocol was published on the registry and results database of ClinicalTrials.gov 
(www.ClinicalTrials.gov; identifier: NCT01437644). The trial was registered on the 
European Clinical Trials Database: 2010-023240-33. 
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Assessed for Eligibility
Patients on waiting list for hip 
surgery (n=160)
Consent / Baseline / Pre-operative 
Assessment
Information sheet and consent; pre-
treatment questionnaire (n=61)
Excluded
Eligibility criteria
1. Child younger than 2 or older than 15 
years (n=6)
2. Child had an acute and current 
systemic infection or illness (n=0)
3. Child had botulinum toxin injections 
within past 4 months (n=2)
4. Child had a previous reaction to 
botulinum toxin (n=0)
5. Child received or will receive 
medications which might interact with 
botulinum toxin (n=0)
6. Insufficient understanding of trial by 
parent or carer in investigator’s opinion 
(n=1)
7. This child does not have a diagnosis of 
hypertonic cerebral palsy (n=29)
8. The child has a GMFCS level of III or 
below (n=14)
9. The child can communicate verbally 
(not appropriate for use of PPP) (n=27)
10. Declined to be involved (n=8)
Other
1. Unable to have injections due to 
clotting complications/hip spica (n=3)
2. Deceased on waiting list (n=2)
3. Not fit to have surgery (n=7)
Randomisation
Randomised 1:1 using minimisation, 
balanced by age and extent of 
surgery (n=54)
Botulinum Toxin Type A
>7 years old (n=14)
Bilateral surgery (n=21)
Received randomised 
intervention (n=27)
Placebo (saline) 
>7 years old (n=14)
Bilateral surgery (n=20)
Received randomised 
intervention (n=27)
Available data (at 
discharge) (n=23)
Withdrawn (n=0)
Allocation: 
Participants & 
randomisation 
balancing
Withdrawn (n=1)
 Patient died (n=1)
Could not be 
contacted (n=0)
Withdrawn (n=0)
Could not be 
contacted (n=2)
Withdrawn (n=0)
Could not be 
contacted (n=0)
Analysed (n=27)
Excluded (n=0)
Analysis
In-patient period (<24 
hours, 2 days and 
subsequent days until 
discharge)
In-clinic period (week 
6)
Available data (at 5 
weeks) (n=24)
Available data (at 6 
weeks) (n=24)
Available data (at 
discharge) (n=26)
Available data (at 5 
weeks) (n=24)
Available data (at 6 
weeks) (n=26)
At home period 
(weeks 2, 3, 4 and 5)
Withdrawn (n=0)
Could not be 
contacted (n=1)
Withdrawn (n=0)
Could not be 
contacted (n=1)
Withdrawn (n=2):
 Reaction to 
 anaesthetic (n=1)
 Surgery cancelled due 
 to illness (n=1)
Not randomised
1. Not fit to have surgery (n=4)
2. Not requiring bony surgery (n=1)
3. Surgery postponed (n=2)
Analysed (n=27)
Excluded (n=0)
Withdrawn (n=0)
Could not be 
contacted (n=2)
 
Figure 1. CONSORT diagram of POPPIES trial. 
